BIOMAT Database Logo BIOMAT Database Logo

Treatment of anthracycline extravasation with dexrazoxane -- clinical experience. 2006

Annette Frost, and Daniela Gmehling, and Marc Azemar, and Clemens Unger, and Klaus Mross
Tumor Biology Center at the Albert Ludwigs University, Freiburg i.Br., Germany.

BACKGROUND Accidental extravasation is a severe complication when administering anthracyclines. We describe 3 cases of extravasation with 3 different anthracyclines. METHODS One patient came from another hospital for a second opinion after an epirubicin extravasation. Only surgical debridement of the necrotic tissue was possible. The other two extravasations occurred during treatment with doxorubicin and doxorubicin- EMCH, respectively, in our department. Both patients were treated with dexrazoxane within 6 h of the event. RESULTS The 2 patients treated with dexrazoxane recovered completely without any sequelae. CONCLUSIONS Treatment of antracycline extravasation with dexrazoxane is potentially useful and safe.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011929 Razoxane An antimitotic agent with immunosuppressive properties. ICRF-159,ICRF-186,NSC-129943,Razoxane Mesylate, (R)-Isomer,Razoxane, (R)-Isomer,Razoxin,ICRF 159,ICRF 186,ICRF159,ICRF186,NSC 129943,NSC129943
D005119 Extravasation of Diagnostic and Therapeutic Materials The escape of diagnostic or therapeutic material from the vessel into which it is introduced into the surrounding tissue or body cavity. Extravasation of Contrast Media,Extravasation of Diagnostic, Therapeutic Materials,Contrast Media Extravasation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Annette Frost, and Daniela Gmehling, and Marc Azemar, and Clemens Unger, and Klaus Mross
Treatment of anthracycline extravasation with dexrazoxane.
September 2000, Clinical cancer research : an official journal of the American Association for Cancer Research,
Annette Frost, and Daniela Gmehling, and Marc Azemar, and Clemens Unger, and Klaus Mross
Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation.
May 2010, The Annals of pharmacotherapy,
Annette Frost, and Daniela Gmehling, and Marc Azemar, and Clemens Unger, and Klaus Mross
Dexrazoxane treatment for intrathoracic anthracycline extravasation.
November 2008, Onkologie,
Annette Frost, and Daniela Gmehling, and Marc Azemar, and Clemens Unger, and Klaus Mross
Dexrazoxane for anthracycline extravasation.
August 2007, Expert review of anticancer therapy,
Annette Frost, and Daniela Gmehling, and Marc Azemar, and Clemens Unger, and Klaus Mross
Dexrazoxane in anthracycline extravasation.
August 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Annette Frost, and Daniela Gmehling, and Marc Azemar, and Clemens Unger, and Klaus Mross
Anthracycline extravasation injuries: management with dexrazoxane.
April 2009, Therapeutics and clinical risk management,
Annette Frost, and Daniela Gmehling, and Marc Azemar, and Clemens Unger, and Klaus Mross
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.
March 2007, Annals of oncology : official journal of the European Society for Medical Oncology,
Annette Frost, and Daniela Gmehling, and Marc Azemar, and Clemens Unger, and Klaus Mross
Dexrazoxane efficacy for anthracycline extravasation: use in UK clinical practice.
March 2013, International journal of clinical practice,
Annette Frost, and Daniela Gmehling, and Marc Azemar, and Clemens Unger, and Klaus Mross
[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
January 2010, Nederlands tijdschrift voor geneeskunde,
Annette Frost, and Daniela Gmehling, and Marc Azemar, and Clemens Unger, and Klaus Mross
Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone.
January 2006, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!